The All Wales Medicines Strategy Group has recommended that Sprycel (dasatinib), which is manufactured by US drug major Bristol-Myers Squibb, should be used within the National Health Service in Wales for the treatment of adults with chronic or accelerated phase chronic myeloid leukemia, where there is resistance or intolerance to prior therapy including Novartis' Glivec/Gleevec (imatinib mesylate).
The disease is rare, but accounts for around 15% of all leukemias, with about 2,600 people in the UK currently affected by CML. The condition progresses through three stages: chronic, accelerated and blast. Sprycel was not recommended by the AWMSG in blast phase patients. However, B-MS notes that, because most CML patients are diagnosed in the chronic phase, this recommendation will encompass the majority of eligible patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
| Headless Content Management with Blaze